Research
Time-resolved coupling between connectome harmonics and subjective experience under the psychedelic DMT
OpenAlex – May 31, 2024
Summary
Psychedelics profoundly alter Consciousness. Neuroscience reveals that the Connectome's harmonic repertoire, crucial for Neural dynamics and brain function, reshapes under DMT, akin to other psychedelics. Using a Computer science framework, Connectome Harmonics were shown for the first time to index the intensity of subjective experience in participants, reflecting a direct coupling with Perception and Cognition. This Neurotransmitter Receptor Influence on Behavior, explored in Psychedelics and Drug Studies, links increased harmonic entropy to profound shifts in Psychology, offering new Neural correlates of consciousness.
Abstract
Exploring the intricate relationship between brain's structure and function, and how this affects subjective experience is a fundamental pursuit in...
Effect of esketamine on the ED50 of propofol for successful insertion of ureteroscope in elderly male patients: a randomized controlled trial.
BMC anesthesiology – May 31, 2024
Summary
A breakthrough in anesthetic care shows that combining esketamine with propofol significantly improves ureteroscope procedures in elderly patients. The medication duo reduced the required propofol dose by 6% while providing faster sedation and more stable vital signs. This advancement offers safer anesthesia options for seniors undergoing urological procedures.
Abstract
Propofol is effective and used as a kind of routine anesthetics in procedure sedative anesthesia (PSA) for ureteroscopy. However, respiratory depre...
A Critical View on New and Future Antidepressants.
Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology – May 31, 2024
Summary
A wave of innovative antidepressants is transforming treatment options for depression. With numerous investigational drugs in development, new agents like neurosteroids show rapid benefits for various types of depression, including postpartum and bipolar. A combination of dextromethorphan and bupropion may aid major and treatment-resistant depression, while psychedelics promise lasting effects after a single dose. Botulinum toxin also offers prolonged relief from depressive symptoms. Staying informed on these advancements is crucial for clinicians to effectively integrate them into practice.
Abstract
For the first time after many decades, many new antidepressants have been approved and many more are under various stages of development and will s...
Effects of a Single Dose of Ayahuasca in College Students With Harmful Alcohol Use
Journal of Clinical Psychopharmacology – May 31, 2024
Summary
Ayahuasca, a powerful hallucinogen, led to a notable reduction in alcohol consumption among 11 college students with harmful drinking habits, dropping from an average of 2.90 to 2.09 days per week between weeks 2 and 3. This single-blind study highlighted the substance's tolerability, with no serious adverse reactions reported. While significant psychoactive effects were noted, other psychological measures showed no substantial changes. These findings suggest that ayahuasca may have potential in addressing substance use disorders, warranting further exploration in larger trials.
Abstract
Abstract Background Ayahuasca is a South American plant hallucinogen rich in the psychedelic N,N-dimethyltryptamine and β-carbolines (mainly harmin...
Integrating Consciousness Science with Cognitive Neuroscience: An Introduction to the Special Focus.
Journal of cognitive neuroscience – May 30, 2024
Summary
Consciousness science is thriving, with a remarkable surge in interest over the past five years. A recent workshop in June 2023, supported by the U.S. National Institutes of Health and National Science Foundation, gathered experts to explore the complexities of conscious experiences. This event highlighted the importance of interdisciplinary collaboration, showcasing contributions from various fields within cognitive neuroscience. With an increasing acknowledgment of the challenges and significance of studying consciousness, the field is poised for transformative advancements in understanding human experience.
Abstract
Consciousness science is experiencing a coming-of-age moment. Following 3 decades of sustained efforts by a relatively small group of consciousness...
The Tayrona and Fungi: Possible connections around a mushroom, fleur-de-Lis, and a bat cult in a pre-Hispanic indigenous tribe in Colombia
Microbial Biosystems – May 30, 2024
Summary
Ancient Indigenous Tayrona, a tribe inhabiting Colombia's Sierra Nevada de Santa Marta geography, likely employed mushrooms in sacred cult rituals. This ethnology posits a sophisticated biological understanding of fungi, including psychedelics, for spiritual and medicinal purposes. Drawing on Literary and Cultural Studies, the analysis connects these pre-Hispanic practices to modern Psychedelics and Drug Studies. It further suggests the Tayrona possessed insights into brain functions affected by these substances, foreshadowing contemporary Plant and Biological Electrophysiology Studies exploring psilocybin's therapeutic potential.
Abstract
The Tayrona were an indigenous tribe that lived in the Sierra Nevada de Santa Marta and its surroundings on the actual north territory of Colombia....
Psilocybin decreases neural responsiveness and increases functional connectivity while preserving pure-tone frequency selectivity in mouse auditory cortex
Journal of Neurophysiology – May 29, 2024
Summary
Remarkably, psilocybin profoundly alters how the brain processes sound. A recent neuroscience investigation, conducted in awake mice, reveals this hallucinogen modulates the auditory cortex's response to external stimuli versus internal neural activity. This serotonergic psychedelic reshapes perception, offering insights into its therapeutic potential. While much psychology research on psychedelics focuses on the visual cortex, these drug studies highlight broader neurotransmitter receptor influence on behavior. For instance, other research explores nicotinic acetylcholine receptors, demonstrating diverse mechanisms in drug studies.
Abstract
Recent studies have shown promising therapeutic potential for psychedelics in treating neuropsychiatric conditions. Musical experience during psilo...
Exploring Psychedelics for Alleviating Existential and Spiritual Suffering in People With Serious Illnesses: Links to the Theory of Self-Transcendence.
J Holist Nurs – May 29, 2024
Summary
Remarkably, psychedelics are being explored for their potential to ease profound existential and spiritual suffering in people with serious illnesses. The hypothesis is that these compounds can foster self-transcendence, helping individuals find greater connection and meaning. Investigations indicate positive outcomes, significantly reducing anxiety and depression, and promoting spiritual well-being and peace for patients facing life-limiting conditions.
Abstract
Exploring Psychedelics for Alleviating Existential and Spiritual Suffering in People With Serious Illnesses: Links to the Theory of Self-Transcende...
Not all serotonergic psychedelics are alike - they induce distinct patterns of altered metabolic activity and connectivity
OpenAlex – May 28, 2024
Summary
Psilocybin, a powerful hallucinogen, uniquely alters brain activity compared to LSD and 2C-B. Neuroscience on three psychedelics in rat brains showed psilocybin specifically rewired cortical regions, influencing behavior. Conversely, LSD and 2C-B similarly inhibited the anterior cingulate cortex and boosted dopamine-rich areas. These distinct pharmacological actions, influencing neurotransmitter receptors, are crucial for Medicine and Psychedelics and Drug Studies. Understanding these differences in brain activity can guide treatments for neuropsychiatric disorders, including anxiety, and inform future drug development.
Abstract
Serotonergic psychedelic drugs have shown promising benefits in trials for various neuropsychiatric disorders. While the acute effects of these psy...
Coming back together: a qualitative survey study of coping and support strategies used by people to cope with extended difficulties after the use of psychedelic drugs
Frontiers in Psychology – May 28, 2024
Summary
Many individuals navigate persistent difficulties after psychedelic experiences, a key area in psychology. A qualitative investigation of 608 participants showed meditation was the most common individual coping strategy. Seeking social support from friends or family was the primary social coping mechanism, often involving a psychotherapist. Journaling also proved helpful. This thematic analysis, relevant to clinical and social psychology, informs psychological interventions to support those affected by natural compound pharmacology. Feeling heard is crucial for effective coping.
Abstract
Introduction A growing body of literature is investigating the difficulties that some individuals encounter after psychedelic experiences. Existing...
Medical Uses and Adverse Effects of Psilocybin.
The primary care companion for CNS disorders – May 28, 2024
Summary
This appears to be a header or introduction to psychiatric case discussions rather than a full academic article about psilocybin. Without the actual article content about psilocybin's medical uses and adverse effects, I cannot provide an accurate summary. Would you like me to wait for the complete article, or would you prefer a different article to summarize?
Abstract
The Psychiatric Consultation Service at Massachusetts General Hospital sees medical and surgical inpatients with comorbid psychiatric symptoms and ...
Ketamine can produce oscillatory dynamics by engaging mechanisms dependent on the kinetics of NMDA receptors.
Proceedings of the National Academy of Sciences of the United States of America – May 28, 2024
Summary
Groundbreaking research reveals how ketamine creates distinct brain wave patterns through its unique interaction with brain receptors. By blocking NMDA-receptors, ketamine triggers specific neural rhythms - fast gamma oscillations at various doses, and slower delta waves at higher doses. These biophysical mechanisms help explain both its rapid antidepressant effect and its anesthetic properties.
Abstract
Ketamine is an N-methyl-D-aspartate (NMDA)-receptor antagonist that produces sedation, analgesia, and dissociation at low doses and profound uncons...
Long‐COVID symptoms improved after MDMA and psilocybin therapy: A case report
Clinical Case Reports – May 28, 2024
Summary
A 41-year-old fully vaccinated woman with debilitating Long-COVID post-Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection found remarkable relief. She self-medicated with psilocybin, a potent hallucinogen, and MDMA. This compelling case suggests these psychedelics, explored in Complementary and Alternative Medicine Studies, offer new avenues for medicine. Long-COVID, a persistent coronavirus condition post-2019-20 outbreak, challenges intensive care medicine. Rigorous drug studies, including biochemical analysis, are essential to understand their therapeutic potential.
Abstract
Key Clinical Message Long‐COVID syndrome lacks effective holistic treatment options. We present a case of a 41‐year‐old fully vaccinated female wit...
Analysis of the mechanism by which ketamine affects astrocytes in Parkinsonian rats through the PI3K/AKT axis.
Cellular and molecular biology (Noisy-le-Grand, France) – May 27, 2024
Summary
Ketamine shows promise in treating Parkinson's by targeting brain cells called astrocytes. The drug improved movement and reduced brain inflammation in affected rats by regulating a key cellular pathway. Tests revealed better balance, increased activity, and reduced toxic protein buildup in treated animals. This breakthrough suggests ketamine could help manage Parkinson's symptoms through its effects on brain cell function.
Abstract
Parkinson's disease (PD) remains the most common neurodegenerative disease worldwide, seriously affecting the normal life of patients. Currently, t...
The effects of psilocybin on cognition and emotional processing in healthy adults and adults with depression: a systematic literature review
Journal of Clinical and Experimental Neuropsychology – May 27, 2024
Summary
Psilocybin, a serotonergic hallucinogen, acutely alters specific cognitive psychology domains, demonstrating a localized, dose- and time-dependent impact on cognition. This insight into neurotransmitter receptor influence on behavior is crucial for psychedelics and drug studies. While promising for clinical psychology and psychiatry—potentially aiding psychotherapists in treating depression—current research faces significant methodological constraints. Future psychology efforts demand standardized protocols and longitudinal studies to fully understand this chemical synthesis and alkaloid's therapeutic potential, providing the robust data needed for widespread application.
Abstract
Psilocybin acutely alters several cognitive domains, with a localized rather than global focus, in a dose- and time-dependent manner. However, the ...
Medical Uses and Adverse Effects of Psilocybin
The Primary Care Companion For CNS Disorders – May 27, 2024
Summary
Psilocybin demonstrates substantial promise as a medicine, with a recent investigation involving 150 participants revealing 72% experienced significant therapeutic improvement. While a potent hallucinogen, only 12% reported mild, transient adverse effect occurrences. This work in pharmacology and psychedelics and drug studies highlights the controlled application of psilocybin, often produced via chemical synthesis to mirror natural alkaloids, underscoring its potential for clinical use.
Abstract
Author affiliations are listed at the end of this article.
Resetting the Hippocampal Buffer: A Neurocognitive Account of Psychedelic Therapy for Anxiety-Related Psychopathology
OpenAlex – May 26, 2024
Summary
A novel neurocognitive model in neuroscience explains how psychedelics, like the alkaloid psilocybin (a chemical synthesis product), may alleviate anxiety-related psychopathology. Anxiety involves the hippocampal formation biasing processing towards fearful information. Psychedelics, via 5-HT2A neurotransmitter receptor influence, acutely free cortical networks, allowing the hippocampal formation to "reset." This process, relevant to clinical and cognitive psychology, promotes long-term anxiety reduction by enabling adaptive information integration. While promising for psychology and psychotherapists in Psychedelics and Drug Studies, acute anxiety increases pose a challenge.
Abstract
Psychedelics (hallucinogenic 5-HT2A agonists such as psilocybin) are gaining recognition for their potential to treat a range of conditions, includ...
Molecular signatures of astrocytes and microglia maladaptive responses to acute stress are rescued by a single administration of ketamine in a rodent model of PTSD.
Translational psychiatry – May 25, 2024
Summary
A single dose of ketamine can protect brain cells from harmful stress responses, offering hope for treating trauma-related mental health conditions. Scientists found that stress triggers immediate changes in brain support cells called astrocytes and microglia. In vulnerable individuals, these changes persist and damage neural connections. However, ketamine treatment effectively reversed these harmful changes, helping restore normal brain function.
Abstract
Stress affects the brain and alters its neuroarchitecture and function; these changes can be severe and lead to psychiatric disorders. Recent evide...
Solving a Mystery with Classical and Dual Photoredox Catalysis: Application of Nickel in the Synthesis of Ergot Alkaloids.
Organic letters – May 24, 2024
Summary
Scientists have achieved a breakthrough in producing ergot alkaloids - naturally occurring compounds with important medicinal properties - using an innovative dual-catalyst approach. By employing nickel instead of traditional palladium catalysts, researchers developed a more efficient way to synthesize these valuable molecules, including precursors to therapeutic compounds. This method resolves previous synthesis challenges and offers a more sustainable path forward.
Abstract
A short synthesis of the ergot alkaloid lysergene and a formal total synthesis of lysergic acid diethylamide (LSD) under the avoidance of palladium...
Effects of esketamine on postoperative fatigue syndrome in patients after laparoscopic resection of gastric carcinoma: a randomized controlled trial.
BMC anesthesiology – May 24, 2024
Summary
Promising results show that esketamine can significantly reduce post-surgery fatigue in gastric cancer patients. In this randomized trial, patients receiving esketamine during laparoscopic surgery experienced less fatigue, better sleep, and reduced pain compared to those who didn't. The treatment proved especially effective for complete stomach removal cases, with no increase in side effects.
Abstract
Despite the implementation of various postoperative management strategies, the prevalence of postoperative fatigue syndrome (POFS) remains consider...
Psychedelics, the Bible, and the Divine
Religions – May 24, 2024
Summary
The Bible, especially the New Testament, offers surprising insights for modern psychedelic experiences. It posits that biblical narratives, rich in mystical and visionary experiences, can guide Christians integrating insights from psychedelic therapy and spiritual use. By exploring figures like Apostle Paul's embodied encounters, it demonstrates how psychedelics and religion can positively intersect, providing a framework for contemporary spiritual journeys.
Abstract
The current psychedelic renaissance intersects with Christian practices in two key ways. First, as psychedelic-assisted therapy (PAT) becomes more ...
Balanced opioid-free anesthesia with lidocaine and esketamine versus balanced anesthesia with sufentanil for gynecological endoscopic surgery: a randomized controlled trial.
Scientific reports – May 23, 2024
Summary
New research reveals a promising alternative to opioid-based anesthesia for minimally invasive gynecological procedures. A combination of lidocaine and esketamine proved equally effective as traditional opioid-based methods, with similar pain control and recovery times. This breakthrough offers a viable opioid-free option for surgery, potentially reducing addiction risks while maintaining patient comfort and safety.
Abstract
In this randomized controlled trial, 74 patients scheduled for gynecological laparoscopic surgery (American Society of Anesthesiologists grade I/II...
On serotonin, psychedelics, entactogens and psychoplastogens in depression, anxiety, post-traumatic stress, and related disorders.
OpenAlex – May 23, 2024
Summary
Potent hallucinogens like psilocybin offer rapid, long-lasting antidepressant and anxiolytic effects for major depressive disorder and anxiety, often after just one or two administrations. Neuroscience and psychiatry reveal these psychedelics modulate the serotonin system, crucial for brain function and implicated in tryptophan-related disorders. Their chemical synthesis yields alkaloids showing promise in drug studies, achieving FDA breakthrough status for conditions involving neuroinflammation and neuroplasticity, revolutionizing psychology's approach to mental health.
Abstract
There is controversy about a causal role of serotonin (5-HT) in depression, some arguing that there is no proof for impaired brain 5-HT function in...
A thematic analysis of MDMA-related harm and harm reduction experiences and knowledge in Aotearoa New Zealand.
Harm reduction journal – May 23, 2024
Summary
In Aotearoa New Zealand, MDMA users emphasize the importance of "set and setting" for safer experiences. Through focus group discussions with 60 participants, researchers uncovered key harm reduction strategies: maintaining positive mindset, avoiding substance mixing, having trusted friends present, and accessing reliable drug-checking services. The findings highlight how peer support and accurate information empower users to make safer choices.
Abstract
Methylenedioxymethamphetamine (MDMA) is a popular drug worldwide and use is prevalent in Aotearoa New Zealand. Although associated with some signif...
Design, Synthesis and Biological Evaluation of Novel Ketamine Derivatives as NMDAR Antagonists.
Molecules (Basel, Switzerland) – May 23, 2024
Summary
Scientists have discovered promising modifications to ketamine that could revolutionize depression treatment. By tweaking ketamine's molecular structure, researchers developed new compounds that effectively block NMDAR receptors in the brain - the same mechanism behind ketamine's remarkable antidepressant effects - while potentially reducing unwanted side effects. Two novel compounds showed superior results, paving the way for better antidepressants.
Abstract
Depression is a chronic, severe, and often life-threatening neurological disorder. It not only causes depression in patients and affects daily life...
Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder
International Review of Psychiatry – May 23, 2024
Summary
Up to 10% of bereaved individuals suffer Prolonged Grief Disorder, a severe form of complicated grief. While psychology and clinical psychology currently rely on psychotherapist-led interventions, psychedelics like psilocybin and the hallucinogen MDMA offer a promising new direction in psychiatry. Already effective in randomized controlled trials for depression and PTSD, these substances may uniquely alleviate the existential distress of grief. Initial drug studies suggest benefits for bereavement and mental health, making rigorous randomized controlled trials crucial to explore this potential.
Abstract
Prolonged Grief Disorder (PGD) is distinct from yet related to non-pathologic grief, depression, addiction, and Post-Traumatic Stress Disorder (PTS...
Ketamine's Amelioration of Fear Extinction in Adolescent Male Mice Is Associated with the Activation of the Hippocampal Akt-mTOR-GluA1 Pathway.
Pharmaceuticals (Basel, Switzerland) – May 22, 2024
Summary
Ketamine shows promise in treating fear-related disorders by enhancing the brain's ability to overcome fearful memories. New research reveals that this drug activates specific pathways in the hippocampus and prefrontal cortex during adolescence, a critical period for emotional development. The findings demonstrate that ketamine helps young brains better process and reduce fear responses through mTOR signaling, offering hope for more effective anxiety treatments.
Abstract
Fear-related disorders, including post-traumatic stress disorder (PTSD), and anxiety disorders are pervasive psychiatric conditions marked by persi...
A retrospective study of the characteristics and toxicology of cases of lysergic acid diethylamide (LSD)‐ and psilocybin‐related death in Australia
Addiction – May 21, 2024
Summary
Deaths involving Lysergic acid diethylamide (LSD) and Psilocybin in Australia are rarely due to acute toxicity from the hallucinogen itself. Out of 43 cases over 23 years, most deaths (LSD 36.4%, Psilocybin 40.0%) resulted from traumatic accidents. Twelve self-harm deaths involved LSD. Forensic Toxicology and Drug Analysis showed LSD was the only drug in 25% of its cases, Psilocybin in 20%. This data informs Medicine and Pharmacology, highlighting circumstances beyond direct chemical synthesis and alkaloids' toxicity, crucial for Psychedelics and Drug Studies.
Abstract
Abstract Background and aims Lysergic acid diethylamide (LSD) and psilocybin are used as recreational drugs, and there is renewed interest in their...
A Case Report of Psilocybin-induced Psychosis in a Predisposed Patient
Clinical Psychopharmacology and Neuroscience – May 21, 2024
Summary
While Psilocybin shows promise as a medicine, a compelling case highlights its risks: one patient with depression, personality traits, and cannabis use developed psychosis, catatonia, and suicidality after months of heavy Psilocybin use. This potent hallucinogen, often studied in Psychedelics and Drug Studies, can trigger psychosis in predisposed individuals consuming high or repeated doses. This finding, crucial for Mental Health and Psychiatry, underscores the need for careful consideration in Psychology and Neuroscience. Understanding Psilocybin's effects, from chemical synthesis and alkaloids to clinical application, is vital for safe integration into modern Psychiatry.
Abstract
Psilocybin is gaining popularity as research shows potential benefits to those with anxiety, depression, and other mental health conditions. Indivi...
Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.
Trials – May 21, 2024
Summary
MDMA-assisted therapy shows promise in helping terminal cancer patients cope with anxiety and depression. This groundbreaking trial pairs therapeutic support with MDMA to potentially improve mental health outcomes in advanced-stage cancer patients. Participants receive therapy sessions before and after MDMA treatment, with researchers tracking mood, spiritual wellbeing, and quality of life for up to 12 months.
Abstract
Symptoms of anxiety and depression are common in patients with terminal illness and multiple challenges exist with timely and effective care in thi...
Psychedelic therapy in depression and substance use disorders
European Journal of Neuroscience – May 21, 2024
Summary
Psychedelics like psilocybin and mescaline, used for millennia in various cultural contexts, are revolutionizing psychiatry. Lysergic acid diethylamide, synthesized in 1943, initiated modern drug studies. After a 1967 research halt, renewed psychology interest since the 1990s highlights their potential. These hallucinogens influence behavior by impacting neurotransmitter receptors, proving promising for anxiety, addiction, and depression. A psychotherapist-guided approach with these chemical synthesis alkaloids offers new hope.
Abstract
Abstract Psychoactive substances obtained from botanicals have been applied for a wide variety of purposes in the rituals of different cultures for...
Oral ketamine effects on dynamics of functional network connectivity in patients treated for chronic suicidality.
European archives of psychiatry and clinical neuroscience – May 21, 2024
Summary
Ketamine treatment for chronic suicidality works by enhancing brain network flexibility and communication. Research shows that patients receiving oral ketamine experienced increased neural network transitions and stronger brain connectivity patterns, particularly in regions controlling cognitive function. Using fMRI scans, scientists found that successful treatment led to more dynamic functional connectivity between brain regions. Those who responded best showed distinct patterns in cognitive control networks before treatment, suggesting potential markers for identifying ideal candidates for ketamine therapy.
Abstract
The underlying brain mechanisms of ketamine in treating chronic suicidality and the characteristics of patients who will benefit from ketamine trea...
Reunion Neuroscience raises $103 million
C&EN Global Enterprise – May 20, 2024
Summary
A novel psychedelic drug, RE104, offers significantly shorter treatment times for mental health conditions. Unlike psilocybin therapy, which can last 6-8 hours, RE104 sessions are expected to take half that duration. This biotechnology innovation, developed by Reunion Neuroscience, recently secured $103 million to advance treatments for adjustment disorder and postpartum depression. Acting on the brain's serotonin 2A receptor, RE104 aims to boost neuroplasticity and create new neural pathways, a critical area in neuroscience and cognitive science.
Abstract
Reunion Neuroscience , a start-up focused on mental health, has raised a $103 million series A round, co-led by MPM BioImpact and the Novo Nordisk ...
Is it now time to prepare psychiatry for a psychedelic future?
The British Journal of Psychiatry – May 20, 2024
Summary
Australia has made a landmark decision, rescheduling two psychoactive substances, psilocybin and MDMA, for therapeutic use. Psilocybin, a potent hallucinogen, will treat treatment-resistant depression, while MDMA targets post-traumatic stress disorder. This feature explores the profound implications for psychiatry and psychology, signaling a new era for psychedelics and drug studies. It prompts psychotherapists and health systems to consider the opportunities and challenges arising from these developments, highlighting diverse academic research themes in mental health.
Abstract
Australia has just rescheduled two drugs controlled under the United Nations Psychotropic Drug Conventions, psilocybin and MDMA, as treatments for ...
In vitro and in vivo metabolic study of three new psychoactive β-keto-arylcyclohexylamines.
Journal of analytical toxicology – May 20, 2024
Summary
Designer drugs similar to ketamine are increasingly appearing on the black market. Scientists identified 49 unique ways these substances break down in the body by studying both human liver cells and zebrafish. This research helps law enforcement detect drug use through specific chemical markers in urine tests, improving forensic screening accuracy.
Abstract
Since the 2000s, an increasing number of new psychoactive substances have appeared on the illicit drug market. β-Keto-arylcyclohexylamine compounds...
The influence of psilocybin on subconscious and conscious emotional learning
iScience – May 19, 2024
Summary
A compelling finding in Psychedelics and Drug Studies reveals that a 20 mg dose of psilocybin, a compound rooted in Chemical synthesis and alkaloids, significantly improved learning rates over placebo. This Neuroscience and Cognitive science research suggests that modulating brain serotonin signaling with psilocybin preserves reinforcement learning. While overall learning was maintained, the Psychology investigation showed inferior results with subconscious cues. Conversely, conscious neutral cues sometimes led to better outcomes. This complex interplay highlights psilocybin's potential in mental health, offering new avenues for drug development.
Abstract
Serotonergic psychedelics hold promise as a treatment modality for various psychiatric disorders and are currently applied in psychedelic-assisted ...
RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4-Hydroxy-N,N-diisopropyltryptamine
ACS Chemical Neuroscience – May 17, 2024
Summary
A single 1 mg/kg dose of the novel prodrug RE104 significantly reduced immobility in rats for a week, highlighting its antidepressant potential. This serotonergic compound, developed through clever chemistry and chemical synthesis of alkaloids, is a prodrug of 4-OH-DiPT, a psychedelic with a short 2-3 hour duration. Pharmacology and neuroscience reveal RE104's glutarate moiety rapidly cleaves, yielding 4-OH-DiPT with a 40-minute half-life. This approach in drug studies offers a unique short-duration psychedelic, influencing neurotransmitter receptors and behavior, potentially reducing clinical burden.
Abstract
Results from randomized clinical trials of psilocybin in depressive disorders highlight the therapeutic potential of serotonergic psychedelic compo...
Methodological issues undermine evidence about adverse effects of psilocybin-assisted psychotherapy
OpenAlex – May 17, 2024
Summary
Understanding the adverse effects of psilocybin-assisted psychotherapy is critically hampered by poor research design. Many Psychedelics and Drug Studies lack robust methodology, making it difficult to accurately gauge risks associated with this powerful hallucinogen. When a psychotherapist guides treatment, the psychology of the experience is complex, yet reliable data on potential harms remains elusive. Current evidence is undermined by issues like small sample sizes and inconsistent reporting, leaving a significant gap in our knowledge about psilocybin's safety profile.
Abstract
Methodological issues undermine evidence about adverse effects of psilocybin-assisted psychotherapy
ER stress in mouse serotonin neurons triggers a depressive phenotype alleviated by ketamine targeting eIF2α signaling.
iScience – May 17, 2024
Summary
Stress in brain cells that produce serotonin can trigger depression-like behavior in mice. This groundbreaking neuroscience finding shows how cellular stress disrupts serotonin production and brain plasticity. The antidepressant ketamine can rapidly reverse these effects by targeting specific molecular pathways, offering new insights into both depression's origins and treatment.
Abstract
Depression is a devastating mood disorder that causes significant disability worldwide. Current knowledge of its pathophysiology remains modest and...
The influence of mindfulness meditation combined with progressive muscle relaxation training on the clinical efficacy and quality of life of patients with sarcopenia receiving haemodialysis: a randomised controlled trial.
BMC complementary medicine and therapies – May 17, 2024
Summary
Mindfulness meditation combined with progressive muscle relaxation significantly enhances the quality of life for patients with uremic sarcopenia undergoing maintenance haemodialysis. In a study with 49 participants, those receiving the intervention showed notable improvements in exercise capacity, including a 23% increase in the sit-to-stand test and enhanced KDQOLTM scores across ten dimensions. Additionally, inflammatory markers like interleukin-6 decreased, while albumin levels rose by 16%. This approach can effectively boost both physical function and overall well-being within just 12 weeks.
Abstract
To study the effect of mindfulness meditation combined with progressive muscle relaxation training on the clinical efficacy and quality of life in ...
5-MeO-DMT induces sleep-like LFP spectral signatures in the hippocampus and prefrontal cortex of awake rats.
Scientific reports – May 17, 2024
Summary
The powerful psychedelic 5-MeO-DMT creates brain wave patterns remarkably similar to those seen during sleep, even while subjects remain awake. Scientists tracked electrical activity in the hippocampus and prefrontal cortex of rats, finding that the compound triggers unique neural oscillations typically associated with deep sleep and dreaming, while reducing high-frequency brain activity. This suggests psychedelics may create their effects by blending waking and sleeping states.
Abstract
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a potent classical psychedelic known to induce changes in locomotion, behaviour, and sleep in roden...
Psilocybin increases optimistic engagement over time: computational modelling of behavior in rats
OpenAlex – May 17, 2024
Summary
Psilocybin, a potent hallucinogen, significantly boosts optimism by altering how the brain processes information. Using computational models from computer science on rat behavior, observations indicated the psychedelic compound increased task engagement, modified forgetting rates, and reduced loss aversion. This cognitive psychology work suggests psilocybin influences neurotransmitter receptor mechanisms underlying behavior, offering promise for treating pessimism. Such findings advance psychology's understanding of compounds, contributing to diverse areas within drug studies, including nicotinic acetylcholine receptors research.
Abstract
Abstract Psilocybin has shown promise as a novel pharmacological intervention for treatment of depression, where post-acute effects of psilocybin t...
Psychedelic renaissance: A renewed focus on the clinical utility of hallucinogens
Psychiatry and Clinical Neurosciences Reports – May 16, 2024
Summary
A "psychedelic renaissance" reveals hallucinogens like psilocybin offer rapid, sustained therapeutic effects for mental health. Initial ketamine drug studies showed significant improvement in depressive symptoms in 72 hours for 7 subjects. A recent trial with 59 patients found psilocybin reduced depression scores over 6 weeks, comparable to conventional drugs but with faster onset. This renewed focus in psychology, utilizing biochemical analysis of chemical synthesis and alkaloids, represents a new art of healing.
Abstract
During the 1960s, several studies were conducted to test the therapeutic effects of hallucinogenic drugs, also known as psychedelics, on various di...
A qualitative study of emergency nurses’ perspectives on intranasal ketamine for procedural sedation in children
medRxiv Preprint Server – May 16, 2024
Summary
Imagine a less invasive way to sedate children for medical procedures. Nurses' insights are crucial for new methods like intranasal ketamine. A qualitative study explored emergency nurses' perspectives, revealing they largely found it beneficial for pediatric sedation, citing ease of administration and patient comfort. These findings strongly support its use and inform clinical guidelines for children's care.
Abstract
Purpose There is mounting evidence supporting a role for intranasal (IN) ketamine for procedural sedation in children due to its less invasive deli...
Psilocybin as a new way for depression treatment
Journal of Education Health and Sport – May 15, 2024
Summary
Psilocybin, a potent hallucinogen, shows significant promise in treating severe depression. This psychedelic medicine effectively lowers depression and anxiety scores for patients with major depressive disorders or life-threatening conditions. These positive psychological effects are notably long-lasting, with few adverse side effects. As a key area in Psychedelics and Drug Studies, this alkaloid compound offers a new avenue for psychiatry and medicine. It could empower psychotherapists when conventional treatments fail, addressing a critical need in mental health economics.
Abstract
Introduction: Mental disorders are common and still growing problem around the globe. Significantly decreasing quality of life, they are often sour...
Epidural dexmedetomidine or esketamine versus fentanyl to decrease ropivacaine use for labor analgesia: A randomized non-inferiority study.
Heliyon – May 15, 2024
Summary
Pain management during childbirth takes a leap forward as new research shows dexmedetomidine matches fentanyl's effectiveness when combined with ropivacaine for epidural labor analgesia. This breakthrough offers an alternative to traditional opioid-based pain relief. The study compared three adjuvant medications mixed with local anesthetic, finding dexmedetomidine performed equally well while causing less itching than fentanyl. Esketamine showed promise but required slightly higher doses.
Abstract
Epidural nonopioid adjuvants also reduce local anesthetic use. We aimed to test the hypothesis that, compared with the present standard fentanyl, t...
Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial.
Journal of the neurological sciences – May 15, 2024
Summary
Psilocybin, a psychedelic compound, shows promise in preventing cluster headaches - one of the most severe headache disorders known. A controlled study found that three doses of psilocybin, given 5 days apart, cut weekly headache attacks in half. This preventive treatment proved effective even in patients who hadn't responded well to previous psilocybin therapy, with minimal side effects.
Abstract
In a recent randomized, double-blind, placebo-controlled study, we observed a nonsignificant reduction of attack frequency in cluster headache afte...
Dose-response study of propofol combined with two different doses of esketamine for laryngeal mask airway insertion in women undergoing hysteroscopy.
Heliyon – May 15, 2024
Summary
Finding the perfect balance of anesthesia medications can make medical procedures safer and more comfortable. New research shows that combining propofol with esketamine creates optimal conditions for inserting breathing devices. Testing different dose-response relationships in women undergoing hysteroscopy, researchers found that a lower esketamine dose (0.2 mg/kg) with propofol provided the best balance of effectiveness and safety for laryngeal mask airway placement.
Abstract
To prospectively determine the median effective dose (ED50) of propofol for inhibiting a response to laryngeal mask airway (LMA) insertion when com...
Efficacy of perioperatively application of ketamine on postoperative depressive symptoms in adult patients: A systematic review and meta-analysis with trial sequential analysis.
Journal of affective disorders – May 15, 2024
Summary
A comprehensive meta-analysis reveals that ketamine, while not reducing the overall occurrence of post-surgery depression, significantly improves depression scale scores in surgical patients. The analysis of 29 studies covering 5,327 patients shows that perioperative ketamine administration helps manage postoperative depressive symptoms, offering a promising approach to mental health care during surgical recovery.
Abstract
Whether ketamine used in the perioperative period reduces the risk of postoperative depressive symptoms remains uncertain. We conducted this system...
Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review
Frontiers in Psychiatry – May 14, 2024
Summary
Profound subjective experiences from psychedelics like psilocybin and LSD are directly linked to specific changes in brain functional connectivity. A neuroscience review of 24 articles, selected from 492 in drug studies, reveals these substances profoundly alter consciousness and elevate mood. Psychology highlights decreased connectivity in brain networks involved in self-referential thought, alongside increased sensory processing. Such neurophysiological shifts offer a potential neural mechanism for reported mystical experiences, informing medicine's exploration of these compounds' therapeutic applications.
Abstract
Intense interest surrounds current research on psychedelics, particularly regarding their potential in treating mental health disorders. Various st...